Dermatology Times, April 2020 (Vol. 41, No. 4)

Microneedling plus radiofrequency effective

April 02, 2020

Glynis R. Ablon, M.D., spoke at the 18th annual South Beach Symposium in Miami about why microneedling with radiofrequency is an effective way to combat signs of aging skin. According to Dr. Ablon, benefits include minimal downtime and risk versus other options. 

COVID-19: Experts discuss virulence, potential treatments, controversies

March 31, 2020

Governments and the scientific community are racing to identify new and existing drugs that might help flatten the curve and save lives. Read from experts as they discuss the latest news and research surrounding possible treatments for COVID-19.

A paradigm shift in squamous cell carcinoma treatment

March 30, 2020

Recent advances in systemic therapies have led to the development of PD-1 checkpoint inhibitors, which one expert says may represent a paradigm shift in the treatment and management of patients with locally advanced or metastatic cutaneous squamous cell carcinoma (SCC).

Experts advise caution over early, emerging treatments

March 25, 2020

Experts sent a letter to the White House Coronavirus Task Force March 24, outlining concerns about a growing shortage of medications required for managing patients with lupus and rheumatoid arthritis after President Donald Trump said in a March 19 press conference that the anti-malaria drug hydroxychloroquine could treat COVID-19.

Malaria drug hydroxychloroquine may treat COVID-19

March 20, 2020

As the number of patients infected with COVID-19 continues to rise, several experts are relaying data they say may save lives and change the course of this pandemic. According to Drs. George Martin, Ted Rosen, Sheila Fallon-Friedlander, Albert Yan, and James Treat, recent data provides evidence of the use of HCQ, its dosing, as well as epidemiology insights that will serve all healthcare practitioners in the fight against the novel coronavirus, COVID-19.

Guidance on transitioning psoriasis patients between biologics

March 11, 2020

Switching patients with moderate-to-severe plaque psoriasis from one biologic to another is a multifactorial decision and may depend on safety, efficacy or dosing intervals. Ron Vender, M.D., offers insight into how to switch appropriately.

Abrocitinib works quickly in atopic dermatitis

February 21, 2020

A phase 2 study shows that the oral Janus kinase (JAK) 1 inhibitor abrocitinib quickly improved atopic dermatitis (AD) severity and symptoms versus placebo with some measures achieving statistically significant separation in days.

IL-23 inhibitors may offer psoriasis patients longer-lasting results

February 19, 2020

With extended remissions, high safety and favorable dosing schedules, interleukin (IL)-23 inhibitors are well-suited for a variety of patients with psoriasis, says an expert who spoke at the South Beach Symposium

Disease burden high for adolescents with atopic dermatitis

February 05, 2020

Several new studies indicate that disease burden may be higher in adolescents than in adults with atopic dermatitis, and that adolescents with moderate-to-severe disease may face an even greater unmet therapeutic need.

Lifestyle recommendations may curb eczema symptoms

January 10, 2020

Lifestyle recommendations are a complex aspect of eczema care. There are many things within in a patient's control that can impact severity and dermatologists should try to help patients identify these, one expert says.